Jade Jaffar1, Sofia Unger2, Tamera J Corte3, Michael Keller3, Paul J Wolters4, Luca Richeldi5, Stefania Cerri6, Cecilia M Prêle7, Philip M Hansbro8, William Scott Argraves9, Rema A Oliver10, Brian G Oliver11, Judith L Black12, Janette K Burgess13. 1. The Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, and Royal Prince Alfred Hospital (Sydney Local Health District), Sydney, NSW, Australia. Electronic address: jade.jaffar@sydney.edu.au. 2. The Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia. 3. Sydney Medical School, The University of Sydney, and Royal Prince Alfred Hospital (Sydney Local Health District), Sydney, NSW, Australia. 4. Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA. 5. Department of Respiratory Diseases, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy; Department of Interstitial Lung Disease, University of Southampton, Southampton, England. 6. Department of Respiratory Diseases, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy. 7. Lung Institute of Western Australia, Centre for Asthma Allergy and Respiratory Research, The University of Western Australia, Perth, WA, Australia; Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, The University of Western Australia and Western Australian Institute for Medical Research, Perth, WA, Australia. 8. Priority Research Centre for Asthma and Respiratory Disease, The University of Newcastle and Hunter Medical Research Institute (HMRI), New Lambton Heights, NSW, Australia. 9. Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC. 10. Surgical and Orthopaedic Research Laboratories, Prince of Wales Clinical School, University of New South Wales, Randwick, NSW, Australia. 11. The Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; School of Medical and Molecular Biosciences, The University of Technology Sydney, Sydney, NSW, Australia. 12. The Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia. 13. The Woolcock Institute of Medical Research, The University of Sydney, Glebe, NSW, Australia; Discipline of Pharmacology, The University of Sydney, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, and Royal Prince Alfred Hospital (Sydney Local Health District), Sydney, NSW, Australia.
Abstract
BACKGROUND: The underlying mechanisms of idiopathic pulmonary fibrosis (IPF) are unknown. This progressive disease has high mortality rates, and current models for prediction of mortality have limited value in identifying which patients will progress. We previously showed that the glycoprotein fibulin-1 is involved in enhanced proliferation and wound repair by mesenchymal cells and, thus, may contribute to lung fibrosis in IPF. METHODS: Serum, lung tissue, and lung function values were obtained from four independent locations (Sydney, NSW, and Perth, WA, Australia; San Francisco, CA; and Modena, Italy). Patients with IPF were followed for a minimum of 1 year and progression was defined as a significant decline in lung function or death. Primary parenchymal lung fibroblasts of 15 patients with and without IPF were cultured under nonstimulatory conditions. Fibulin-1 levels in serum, and secreted or deposited by fibroblasts, were measured by western blot and in lung tissue by immunohistochemistry. RESULTS: Serum fibulin-1 levels were increased in patients with IPF compared with subjects without lung disease (P = .006). Furthermore, tissue fibulin-1 levels were increased in patients with IPF (P = .02) and correlated negatively with lung function (r = -0.9, P < .05). Primary parenchymal fibroblasts from patients with IPF produced more fibulin-1 than those from subjects without IPF (P < .05). Finally, serum fibulin-1 levels at first blood draw predicted disease progression in IPF within 1 year (area under the curve , 0.71; 95% CI, 0.57-0.86; P = .012). CONCLUSIONS: Fibulin-1 is a novel potential biomarker for disease progression in IPF and raises the possibility that it could be used as a target for the development of new treatments.
BACKGROUND: The underlying mechanisms of idiopathic pulmonary fibrosis (IPF) are unknown. This progressive disease has high mortality rates, and current models for prediction of mortality have limited value in identifying which patients will progress. We previously showed that the glycoprotein fibulin-1 is involved in enhanced proliferation and wound repair by mesenchymal cells and, thus, may contribute to lung fibrosis in IPF. METHODS: Serum, lung tissue, and lung function values were obtained from four independent locations (Sydney, NSW, and Perth, WA, Australia; San Francisco, CA; and Modena, Italy). Patients with IPF were followed for a minimum of 1 year and progression was defined as a significant decline in lung function or death. Primary parenchymal lung fibroblasts of 15 patients with and without IPF were cultured under nonstimulatory conditions. Fibulin-1 levels in serum, and secreted or deposited by fibroblasts, were measured by western blot and in lung tissue by immunohistochemistry. RESULTS: Serum fibulin-1 levels were increased in patients with IPF compared with subjects without lung disease (P = .006). Furthermore, tissue fibulin-1 levels were increased in patients with IPF (P = .02) and correlated negatively with lung function (r = -0.9, P < .05). Primary parenchymal fibroblasts from patients with IPF produced more fibulin-1 than those from subjects without IPF (P < .05). Finally, serum fibulin-1 levels at first blood draw predicted disease progression in IPF within 1 year (area under the curve , 0.71; 95% CI, 0.57-0.86; P = .012). CONCLUSIONS:Fibulin-1 is a novel potential biomarker for disease progression in IPF and raises the possibility that it could be used as a target for the development of new treatments.
Authors: Christopher J Ryerson; Thomas H Urbania; Luca Richeldi; Joshua J Mooney; Joyce S Lee; Kirk D Jones; Brett M Elicker; Laura L Koth; Talmadge E King; Paul J Wolters; Harold R Collard Journal: Eur Respir J Date: 2012-12-06 Impact factor: 16.671
Authors: W Scott Argraves; Asashi Tanaka; Elizabeth P Smith; Waleed O Twal; Kelley M Argraves; Daping Fan; Christian C Haudenschild Journal: Histochem Cell Biol Date: 2009-08-20 Impact factor: 4.304
Authors: O Le Saux; K Teeters; S Miyasato; J Choi; G Nakamatsu; J A Richardson; B Starcher; E C Davis; E K Tam; C Jourdan-Le Saux Journal: Am J Physiol Lung Cell Mol Physiol Date: 2008-10-10 Impact factor: 5.464
Authors: Gang Liu; Marion A Cooley; Andrew G Jarnicki; Alan C-Y Hsu; Prema M Nair; Tatt Jhong Haw; Michael Fricker; Shaan L Gellatly; Richard Y Kim; Mark D Inman; Gavin Tjin; Peter A B Wark; Marjorie M Walker; Jay C Horvat; Brian G Oliver; W Scott Argraves; Darryl A Knight; Janette K Burgess; Philip M Hansbro Journal: JCI Insight Date: 2016-06-16
Authors: A G Jarnicki; H Schilter; G Liu; K Wheeldon; A-T Essilfie; J S Foot; T T Yow; W Jarolimek; P M Hansbro Journal: Br J Pharmacol Date: 2016-10-12 Impact factor: 8.739
Authors: Gang Liu; Marion A Cooley; Andrew G Jarnicki; Theo Borghuis; Prema M Nair; Gavin Tjin; Alan C Hsu; Tatt Jhong Haw; Michael Fricker; Celeste L Harrison; Bernadette Jones; Nicole G Hansbro; Peter A Wark; Jay C Horvat; W Scott Argraves; Brian G Oliver; Darryl A Knight; Janette K Burgess; Philip M Hansbro Journal: JCI Insight Date: 2019-07-25
Authors: Fengying Tang; Jourdan E Brune; Mary Y Chang; Stephen R Reeves; William A Altemeier; Charles W Frevert Journal: Am J Physiol Cell Physiol Date: 2022-06-01 Impact factor: 5.282